2024
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2023
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2022
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2021
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2020
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2019
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2018
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
2017
Director+ dealing
16 January 2018
Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, has been advised that Sonya Ferguson, Senior Independent Director of the Company, has acquired 15,593 ordinary shares of 4p each in the Company ("Ordinary Shares") at a price of 160p per share. The Ordinary Shares were acquired through her SIPP. Following this purchase, Sonya Ferguson now has a total beneficial interest in 15,593 Ordinary Shares, equivalent to 0.07% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Sonya Ferguson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Fusion Antibodies plc | ||||
| b) | LEI | 213800KBAYRC9VOQ9V39 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.04 each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16 |
||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
N/A | ||||
| e) | Date of the transaction | 15 January 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com |
| Dr Paul Kerr, Chief Executive Officer | Via Walbrook PR |
| James Fair, Chief Financial Officer | |
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 |
| Virginia Bull / James Reeve / Asha Chotai | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus | Mob: +44 (0)7980 541 893 |
| Anna Dunphy | Mob: +44 (0)7876 741 001 |
